According to Acorda Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00697957. At the end of 2023 the company had a P/S ratio of 0.1593.
Year | P/S ratio | Change |
---|---|---|
2023 | 0.1593 | 1.24% |
2022 | 0.1574 | -24.13% |
2021 | 0.2074 | -19.15% |
2020 | 0.2566 | -49.27% |
2019 | 0.5057 | -67.73% |
2018 | 1.57 | -8.06% |
2017 | 1.70 | 2.16% |
2016 | 1.67 | -55.3% |
2015 | 3.73 | -12.43% |
2014 | 4.26 | 20.12% |
2013 | 3.55 | 9.7% |
2012 | 3.23 | -0.04% |
2011 | 3.24 | -41.51% |
2010 | 5.53 | -68.36% |
2009 | 17.5 | 8.11% |
2008 | 16.2 | 1.77% |
2007 | 15.9 | 15.99% |
2006 | 13.7 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Sarepta Therapeutics
SRPT | 8.83 | 126,396.76% | ๐บ๐ธ USA |
Repligen
RGEN | 13.8 | 197,137.08% | ๐บ๐ธ USA |
Affimed
AFMD | 8.50 | 121,673.12% | ๐ฉ๐ช Germany |
BioMarin Pharmaceutical BMRN | 7.02 | 100,479.26% | ๐บ๐ธ USA |